TSCAN THERAPEUTICS, INC. (TCRX) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 7.11M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $7.11M | (m) | (m) |
| 2026-03-31 | (m) | $9.14M | (m) | (m) |
| 2025-12-31 | (m) | $10.32M | (m) | (m) |
| 2025-09-30 | (m) | $8.42M | (m) | (m) |
| 2025-06-30 | (m) | $6.96M | (m) | (m) |
| 2025-03-31 | (m) | $4.42M | (m) | (m) |
| 2024-12-31 | (m) | $2.82M | (m) | (m) |
| 2024-09-30 | (m) | $9.36M | (m) | (m) |
| 2024-06-30 | (m) | $12.20M | (m) | (m) |
| 2024-03-31 | (m) | $14.81M | (m) | (m) |
| 2023-12-31 | (m) | $21.05M | (m) | (m) |
| 2023-09-30 | (m) | $16.93M | (m) | (m) |
| 2023-06-30 | (m) | $16.41M | (m) | (m) |
| 2023-03-31 | (m) | $17.32M | (m) | (m) |
| 2022-12-31 | (m) | $13.54M | (m) | (m) |
| 2022-09-30 | (m) | $13.29M | (m) | (m) |
| 2022-06-30 | (m) | $12.34M | (m) | (m) |
| 2022-03-31 | (m) | $11.13M | (m) | (m) |
| 2021-12-31 | (m) | $10.14M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $1.08M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B |